In our October All-Member Webinar, TpAML co-founder/advocate Julie Guillot and Dr. Gwen Nichols, Chief Medical Officer, Leukemia & Lymphoma Society, highlighted the energy and work behind putting — and keeping — the patient at the center of drug development.
Participants had the opportunity to learn valuable insights on the makings of Target Pediatric AML (that a number of CAC2 members worked together on) and how research findings have spurred the launch of a groundbreaking global master clinical trial initiative in high-risk childhood leukemia, LLS PedAL.
Categories
- Blog Posts (93)
- Explainer Post (12)
- Guest Blogs (15)
- Member Blogs (38)
- Survivorship Matters Blog (9)
- CAC2 News (25)
- Collaborative Achievements (14)
- Community News (247)
- In Memoriam (2)
- News Digest (199)
- Webinars (64)
Tags
Advocacy (55)
Annual Summit (7)
Appropriations (1)
Awareness (26)
AYA (2)
Bereavement (1)
Best Practices (14)
Biorepositories (2)
CAC2 News (9)
CAC2 Project Incubator (1)
CAC2 Projects (11)
Call to Action (25)
Call to Action Prevention (1)
Care Giving (1)
Clinical Trials (11)
COG (2)
Collaboration (14)
Data (15)
Delayed Diagnosis (2)
Digest (12)
Drug Development (11)
Drug Development collaboration (1)
Drug Shortages (2)
Ethics (1)
Family Support (16)
Funding Research (7)
Genomics (6)
Global News (3)
Industry Perspective (5)
Member Access (12)
NCI (3)
Nutrition (2)
Patient-Reported Outcomes (1)
Post-Mortem Tissue Donation (1)
Prevention (4)
Psychosocial Support (6)
Rare and Ultra Rare Cancer (1)
Rare Cancers (1)
Regulations (3)
Research (36)
Research Data (2)
Research Tissue Donation (1)
Social Work (1)
Survivorship (28)
Venture Philanthropy (3)
Recent Posts
- CAC2 Childhood Cancer Community News Digest (October 21-27)
- Readout from October 6 Federal Advocacy Drop-In Session
- CAC2 Childhood Cancer Community News Digest (October 7-20)
- CAC2 Childhood Cancer Community News Digest (September 30-October 6)
- CAC2 Childhood Cancer Community News Digest (September 23-29)